DNA RNA and Cells

02 Jun 2018 Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
02 Jun 2018 Penn-developed Approach Could Limit Toxicity of CAR T Cell Therapy in Acute Myeloid Leukemia
01 Jun 2018 As Anticipated, Sarepta Receives Negative CHMP Opinion for EXONDYS® (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe
01 Jun 2018 Cynata’s Cymerus™ MSCs Effective in Preclinical Model of Diabetic Wounds
01 Jun 2018 Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI
31 May 2018 Mustang Bio Announces Preclinical Data on Potency of its CAR T Cells in Glioblastoma Published in JCI Insight
31 May 2018 APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual Meeting
31 May 2018 CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
31 May 2018 Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
29 May 2018 OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics
29 May 2018 Mesoblast partners with Cartherics to develop ’off-the-shelf’ cell-based immunotherapies for solid cancers
28 May 2018 Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
27 May 2018 Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone
25 May 2018 Enrolment Completed in Cynata’s Phase 1 Clinical Trial of CYP-001 in GvHD
23 May 2018 FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy
23 May 2018 TCR Engineered T-Cells are coming out of the shadow to the light
23 May 2018 Rocket Pharmaceuticals Presents Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in Patients with Fanconi Anemia at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
23 May 2018 Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development
23 May 2018 MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
23 May 2018 Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
23 May 2018 Lupagen & Humanigen to explore point-of-care CAR-T therapy
23 May 2018 uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
22 May 2018 BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress
22 May 2018 Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
22 May 2018 Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up